摘要
以利伐沙班结构为基础,根据其与Ⅹa因子相互作用的特点对其进行结构改造,设计并合成了一系列未见报道的唑烷酮醚类化合物(7a^7m)。所合成化合物结构均经IR,1H NMR和MS确证,并测定了目标衍生物Ⅹa因子抑制活性。实验数据表明,所合成化合物均表现出了一定的Ⅹa因子抑制活性,但活性低于利伐沙班。
According to the binding mode of rivaroxaban in complex with human factor Xa and the chemical structure of rivaroxaban, we have designed and synthesized the oxazolidinone ether compounds, which have not be reported in literatures. The structures of all the rivaroxaban derivatives synthesized were identified by IR, 1 H NMR and MS. The anti-factor Xa activity of the synthesized compounds was tested. The results showed that all of the tested compounds exhibited some activity, yet were less potent than rivaroxaban.
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2013年第5期385-389,共5页
Journal of China Pharmaceutical University
基金
国家“重大新药创制”科技重大专项资助项目(No.2013ZX09301303-002)
江苏省产学研联合创新资金-前瞻性联合研究项目(No.BY2011158)
中央高校基本科研业务费专项基金资助项目(No.JKY2011092)~~